Hyaluronic acid and folic acid-modified mesoporous silica nanoparticles delivering sulforaphane suppress NSCLC via SPI1/miR-616-5p axis Authors: Wujin Li, Changjian Lin, Hang Xu, Wenxiang Yue, Yi Xu, Baosong Xie, Daxuan Wang Published: 2026 ABSTRACT SummarySulforaphane (SF) suppresses NSCLC metastasis by modulating miR-616-5p, which is transcriptionally upregulated by the oncogenic transcription factor SPI1. However, the roles of SF, SPI1, and miR-616-5p in NSCLC metastasis remain unclear. In this study, we found that SPI1 expression in NSCLC tissues positively correlated with miR-616-5p levels, and that SPI1 transcriptionally regulated miR-616-5p to promote NSCLC cell invasion and migration. Further analysis showed that SF directly binds SPI1, inhibiting its activity and downregulating miR-616-5p expression, thereby attenuating NSCLC metastasis. However, the poor stability of SF limits its clinical application. To address this, we developed a mesoporous silica nanoparticle (MSN)-based delivery system modified with hyaluronic acid and folic acid (MSNs@SF-HA-FA), which exhibited good stability, enhanced cellular uptake, and improved tumor targeting and anti-metastatic efficacy in NSCLC xenograft models. Collectively, our findings reveal the SPI1/miR-616-5p axis drives NSCLC metastasis and show that MSNs@SF-HA-FA enhances SF′s anti-metastatic effect, highlighting its clinical potential.Subject areas: Drug delivery system, Nanoparticles, Biological sciences, Cancer, Materials science, Biomaterials Introduction Lung cancer is one of the most common malignancies, causing approximately 1.6 million deaths annually and ranking as the leading cause of cancer-related mortality worldwide.1 Among them, non-small cell lung cancer (NSCLC) accounts for more than 80% of newly diagnosed lung cancer cases.2,3 A recent study predicted that by 2030, the mortality rate associated with NSCLC in China may rise to approximately 40%.4 Although advances in early detection, diagnostic techniques, and targeted interventions have contributed to a decline in lung cancer incidence and mortality, the clinical outcomes for NSCLC patients remain unsatisfactory, with a 5-year survival rate of only 18%.5 Evidence indicates that metastasis is the primary cause of death in NSCLC patients,6 accounting for more than 70% of mortality cases.2 During lung cancer metastasis, tumor cells typically spread through the bloodstream or lymphatic system to distant organs, such as the brain, bone, and lymph nodes.2,7,8 In addition, the primary tumor can facilitate metastatic dissemination of tumor cells by promoting angiogenesis.9 However, effective therapeutic options for distant NSCLC metastasis remain extremely limited, making metastasis the principal cause of lung cancer-related deaths.2 Therefore, elucidating the underlying mechanisms of NSCLC metastasis is crucial not only for improving patients’ quality of life and survival but also for developing more effective therapeutic strategies. Salmonella pathogenicity island 1 (SPI1), also known as the transcription factor PU.1, is an oncogene specifically activated in Friend spleen focus-forming virus-induced acute murine erythroleukemia10 and belongs to the ETS transcription factor family.11 SPI1 was initially identified as a critical regulator of myeloid and B lymphocyte differentiation and development.12 However, accumulating evidence has revealed that SPI1 is overexpressed in a variety of malignancies and is closely associated with tumor cell proliferation and survival.13 Moreover, high levels of SPI1 expression have been shown to correlate with immune cell infiltration, leading to the formation of an immunosuppressive microenvironment and tumor-specific T cell exhaustion, thereby contributing to poor prognosis.14 Thus, SPI1 plays a pivotal role in tumor initiation and progression. Indeed, SPI1 has been implicated in the progression of multiple cancers, including colorectal cancer,15 gastric cancer,16 hepatocellular carcinoma,17 and cervical cancer.18 In NSCLC, SPI1 has been reported to promote tumor progression by activating SNHG6 transcription or through the miR-485-3p/VPS45 axis.19,20 Collectively, these findings indicate that SPI1 is critically involved in NSCLC progression and may serve as a promising therapeutic target. Nevertheless, studies on the underlying mechanisms of SPI1 in NSCLC remain limited, and additional pathways of its action warrant further investigation. Sulforaphane (SF) is a sulfur-containing isothiocyanate phytochemical derived from cruciferous vegetables such as broccoli, cabbage, and kale,21,22 and it exhibits broad anti-inflammatory and antioxidant properties.23 Owing to these characteristics, SF is considered beneficial to human health and is thought to contribute to cancer prevention.24 Recent studies have revealed that SF also exerts anticancer effects by modulating multiple pathways associated with cancer progression,24 including interfering with cell-cycle arrest and apoptosis during the initiation stage of carcinogenesis, as well as regulating the activities of phase I and phase II metabolic enzymes to suppress tumor development.22 A recent report demonstrated that SF can inhibit the development of esophageal squamous cell carcinoma by repressing the expression of mitogen- and stress-activated kinase 2 (MSK2).25 In our previous work, we showed that SF inhibits epithelial-mesenchymal transition (EMT) and metastasis of NSCLC through the miR-616-5p-mediated GSK3β/β-catenin signaling pathway.26 Notably, miR-616-5p, a member of the miR-616 family, functions as an oncogene in multiple cancers by promoting tumor cell proliferation, invasion, and progression.27 Aberrant expression of certain miRNAs and key genes has been shown to drive tumor metastasis,28 while dysregulated transcription factors, as hallmarks of cancer, affect various aspects of tumor biology, including cancer progression, chemoresistance, immune modulation, invasion, and metastasis.28 As a transcription factor, SPI1 plays a critical role in NSCLC.19,20 Therefore, we hypothesize that in addition to regulating miR-616-5p, SF may also exert its anti-NSCLC effects through SPI1, although this possibility requires further investigation. Although SF possesses broad anticancer, antioxidant, and anti-inflammatory activities and has been shown to effectively inhibit the development of various cancers, including NSCLC,26 its inherent instability and sensitivity to oxygen, heat, and alkaline conditions pose significant challenges for pharmaceutical production.22,29 Moreover, SF tends to rapidly accumulate and undergo swift metabolism within cells,30 a phenomenon further validated in animal studies.31 To achieve therapeutic efficacy, a large amount of SF is required, which in turn may cause adverse toxicity.32 These limitations substantially hinder the clinical application of SF. To overcome these challenges, targeted delivery systems, particularly nanomaterial-based carriers, have emerged as a promising and ideal approach.33 Studies have demonstrated that nanocarriers can improve and sustain drug delivery, reduce toxicity and side effects, enhance biodistribution, and prolong drug half-life.34 Among various nanomaterials, mesoporous silica nanoparticles (MSNs) have gained considerable attention due to their unique ordered porous nanostructure, large pore volume, excellent stability, high surface area, acceptable biocompatibility, facile surface functionalization, and efficient loading/release capacity, making them effective intracellular carriers for genes and poorly soluble chemotherapeutics.35 However, premature drug release (“burst effect”) and nonspecific targeting of unmodified MSNs often result in suboptimal anticancer efficacy.36 Therefore, active targeting strategies are frequently employed to minimize off-target effects and maximize cell-specific delivery. In such approaches, the nanoparticle surface can be functionalized with proteins, peptides, aptamers, sugars, vitamins, or antibodies directed against specific surface antigens or unique receptors.37 Folic acid (FA) and hyaluronic acid (HA) are among the most widely used targeting ligands, capable of specifically binding to folate receptors (FR) and CD44 receptors that are overexpressed in many tumors, and have been utilized for MSN surface modification to achieve effective tumor targeting.38,39,40 This strategy has been shown to enhance drug uptake and internalization, enable nanoparticles to effectively evade the reticuloendothelial system, and thereby suppress tumor progression and metastasis.40,41 Therefore, this study aimed to investigate the role of SPI1 in NSCLC and to elucidate its interaction with SF and miR-616-5p. In addition, we synthesized a dual-targeted MSN system modified with HA and FA (MSNs@SF-HA-FA) encapsulating SF. The nanoparticles were characterized in vitro and in vivo, and their tumor-targeting ability and anti-NSCLC efficacy were evaluated. Our results demonstrated that SPI1 promotes tumor cell proliferation, migration, and invasion, and transcriptionally regulates the expression of miR-616-5p. SF exerted anti-metastatic effects on NSCLC by modulating the SPI1/miR-616-5p axis. Meanwhile, the prepared MSNs@SF-HA-FA exhibited favorable morphology, stability, and targeting ability, and suppressed NSCLC progression by inhibiting SPI1 expression. Collectively, these findings suggest that the SPI1/miR-616-5p axis represents a potential therapeutic target for NSCLC, and that MSNs@SF-HA-FA may serve as an effective nanocarrier for the delivery of SF. Results SPI1 promotes NSCLC cell proliferation, migration, invasion, and EMT Previous studies have demonstrated that SPI1 expression is significantly upregulated in NSCLC tissues and cells.20 To further investigate the role of SPI1 in NSCLC, SPI1 overexpression and knockdown were achieved in 95C and 95D cell lines using lentiviral transfection, and transfection efficiency was confirmed by western blot (Figures 1A–1C). Cell counting kit-8 (CCK-8), colony formation, and Transwell assays revealed that SPI1 overexpression significantly enhanced cell viability (p < 0.001), and promoted proliferation (p < 0.01), migration (p < 0.01), and invasion (p < 0.001). In contrast, SPI1 knockdown markedly inhibited cell viability (p < 0.001), proliferation (p < 0.05), migration (p < 0.01), and invasion (p < 0.05) (Figures 1D–1E and 2A). Furthermore, aberrant activation of EMT has been reported to facilitate cancer metastasis.42 To examine the effect of SPI1 on EMT, the expression levels of EMT-related proteins were assessed by western blot. SPI1 overexpression significantly increased N-cadherin and vimentin levels (p < 0.05) while decreasing E-cadherin expression (p < 0.05), whereas SPI1 knockdown produced the opposite effects (Figure 2B). Collectively, these results indicate that SPI1 promotes proliferation, migration, invasion, and EMT in NSCLC cells. SPI1 regulates NSCLC cell viability and proliferation (A–C) Western blot analysis of transfection efficiency for SPI1 overexpression and knockdown (n = 3, n represents biological replicates). (D) CCK-8 assay assessing the effects of SPI1 overexpression and knockdown on NSCLC cell viability (n = 6, n represents biological replicates). (E) Colony formation assay evaluating the impact of SPI1 overexpression and knockdown on NSCLC cell proliferation (n = 3, n represents biological replicates). Data are represented as mean ± SD. p values are based on a one-way ANOVA test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. SPI1 regulates NSCLC cell migration, invasion, and EMT (A) Transwell assay assessing the effects of SPI1 on cell migration and invasion (n = 3, n represents biological replicates), scale bars, 200 μm. (B) Western blot analysis of the impact of SPI1 on the expression levels of EMT-related proteins (N-cadherin, E-cadherin, and vimentin, n = 3, n represents biological replicates). Data are represented as mean ± SD. p values are based on a one-way ANOVA test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Ⅰ, N-cadherin. Ⅱ, E-cadherin. Ⅲ, vimentin. Ⅳ, GAPDH. SPI1 promotes NSCLC cell invasion and migration by transcriptionally regulating miR-616-5p miR-616-5p is significantly upregulated in lung cancer and has been reported to promote NSCLC metastasis and EMT.26 Our previous findings demonstrated that SPI1 enhances the malignant biological behaviors of NSCLC cells. However, whether these effects are mediated through the regulation of miR-616-5p remains unclear. Therefore, to investigate the relationship between SPI1 and miR-616-5p in NSCLC progression, we first examined the expression levels of SPI1 and miR-616-5p in NSCLC tissues by immunohistochemistry (IHC), western blotting, and quantitative reverse transcript-PCR (RT-qPCR). The results showed that both SPI1 and miR-616-5p were markedly upregulated in NSCLC tissues (Figure S1). Further RT-PCR analysis revealed that overexpression of SPI1 significantly increased miR-616-5p expression (p < 0.01), whereas knockdown of SPI1 significantly reduced miR-616-5p expression (p < 0.05) (Figures 3A and 3B), suggesting that SPI1 positively regulates miR-616-5p. To determine whether SPI1 regulates miR-616-5p at the transcriptional level, we performed bioinformatic prediction of potential transcription factors using the TransmiR v3.0 database and the hTFtarget platform. TransmiR v3.0 identified PATZ1, KMT2A, ZNF543, KLF9, and SPI1 as the top five transcription factors most strongly associated with miR-616-5p. Meanwhile, hTFtarget predicted SPI1, MYC, ATF3, BRD3, and BRD4 as the top five candidates with the highest overall likelihood. Cross-analysis of the two prediction results revealed that SPI1 was the only transcription factor ranked among the top five in both databases, indicating that SPI1 may play a central role in the transcriptional regulation of miR-616-5p. This hypothesis was further validated by a luciferase reporter assay. Knockdown of SPI1 significantly reduced luciferase activity (Figure S2), indicating that SPI1 enhances the transcriptional activity of the miR-616-5p promoter. In addition, transwell assays demonstrated that the miR-616-5p inhibitor significantly attenuated the promotive effects of SPI1 overexpression on cell migration and invasion (p < 0.01), whereas the miR-616-5p mimic markedly reversed the inhibitory effects of SPI1 knockdown on migration and invasion (p < 0.05) (Figures 3C–3E). Collectively, these findings indicate that SPI1 promotes NSCLC cell migration and invasion by transcriptionally regulating miR-616-5p. SPI1 promotes NSCLC cell invasion and migration by transcriptionally regulating miR-616-5p (A and B) RT-PCR analysis of miR-616-5p expression following SPI1 overexpression or knockdown (n = 3, n represents biological replicates). (C–E) Transwell assay evaluating cell migration and invasion (n = 3, n represents biological replicates), scale bars, 200 μm. Data are represented as mean ± SD. p values are based on a one-way ANOVA test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Sulforaphane downregulates miR-616-5p activity by directly binding to and inhibiting SPI1 activity SF has been reported to inhibit NSCLC EMT and metastasis via the miR-616-5p-mediated GSK3β/β-catenin signaling pathway.26 In this study, we found that SPI1 regulates the transcription of miR-616-5p. Therefore, we hypothesized that the inhibitory effect of SF on NSCLC might be associated with SPI1. To explore the interaction between SF and SPI1, molecular docking was performed using AutoDock tools. Generally, an absolute value of binding free energy greater than 4.2 kcal/mol indicates binding activity, greater than 5.0 kcal/mol indicates moderate binding affinity, and greater than 7.0 kcal/mol indicates strong binding affinity.43 The docking results (Figure 4A) showed that SF binds to SPI1 with a free binding energy of −5.3 kcal/mol, suggesting a favorable binding interaction. Furthermore, molecular docking analysis revealed that SF forms hydrogen bonds with ARG171 and TYR235 of SPI1, and van der Waals interactions with ASN234, LEU172, TRP213, and ALA231, which stabilize the ligand within the active pocket of SPI1. Surface plasmon resonance imaging (SPRi) was subsequently used to assess the in vitro affinity and interaction kinetics between SF and SPI1. The results (Figure 4B) showed a dissociation constant (KD) of 1.36 × 10−5 M, indicating that SF directly binds to SPI1 in a dose-dependent manner. Western blot analysis (Figures 4C and 4D) demonstrated that SF significantly reduced SPI1 expression in SPI1-overexpressing 95C cells (p < 0.05) and further decreased SPI1 levels in SPI1-knockdown 95D cells (p < 0.05). Additionally, RT-PCR results (Figure 4E) showed that SF significantly downregulated miR-616-5p expression in both SPI1-overexpressing 95C cells and SPI1-knockdown 95D cells (p < 0.01). These findings indicate that SF can directly bind to and inhibit SPI1 activity, thereby downregulating miR-616-5p and exerting therapeutic effects against NSCLC. SF downregulates miR-616-5p activity by directly binding to and inhibiting SPI1 (A) Molecular docking analysis of SF with SPI1. (B) SPRi binding curve of SF to SPI1. (C and D) Western blot analysis of SPI1 expression in cells (n = 3, n represents biological replicates). (E) RT-PCR analysis of miR-616-5p expression in cells (n = 3, n represents biological replicates). Data are represented as mean ± SD. p values are based on a one-way ANOVA test. ∗p < 0.05, ∗∗p < 0.01. Construction and characterization of MSNs@SF-HA-FA nanoparticles To overcome the limitations associated with the clinical application of SF, we designed and fabricated an MSNs-based nanoparticle system encapsulating SF, termed MSNs@SF-HA-FA. The schematic illustration of the preparation process is shown in Figure 5A. Fourier transform infrared (FT-IR) spectroscopy revealed characteristic Si–O–Si peaks at 1040 cm−1 and 810 cm−1, confirming the successful synthesis of MSNs. After SF loading and surface modification with HA, a characteristic –N=C=S peak was observed at 3260 cm−1, indicating successful encapsulation of SF into the MSNs. In addition, a characteristic peak corresponding to the carboxyl (–COOH) group was detected at 1700 cm−1, demonstrating successful HA modification on the MSN surface. Following final FA conjugation, characteristic N–H peaks appeared at 1605 cm−1 and 1532 cm−1 (Figure 5B). Collectively, the FT-IR results confirmed the successful synthesis of MSNs@SF-HA-FA nanoparticles. Transmission electron microscopy (TEM) images (Figure 5C) showed that MSNs exhibited uniform, spherical mesoporous structures. After SF loading and HA-FA modification, the nanoparticles maintained their regular spherical morphology, with a visible HA-FA coating on the surface, indicating that SF loading and HA-FA functionalization did not alter the structural integrity or morphology of the MSNs. Zeta potential analysis (Figure S3) demonstrated that MSNs possessed abundant surface Si–OH groups and exhibited a distinctly negative surface charge (−19.60 ± 0.77 mV). After SF loading, the surface potential remained negative (−20.72 ± 1.34 mV), suggesting that drug encapsulation within the mesopores did not significantly alter the surface chemical properties or compromise particle structure. Following PEI coating, the zeta potential of MSNs@SF shifted from negative to positive (20.39 ± 1.73 mV), indicating successful modification with the cationic polymer and providing favorable conditions for subsequent electrostatic interaction with negatively charged HA. Subsequent HA modification reversed the surface charge back to negative (−20.97 ± 1.73 mV), confirming successful HA coating. Finally, FA conjugation resulted in a slight decrease in the absolute value of the negative surface potential (−15.27 ± 1.14 mV), further verifying the successful functionalization of FA on the nanoparticle surface. Preparation and characterization of MSNs@SF-HA-FA (A) Schematic diagram of the preparation of MSNs@SF-HA-FA. (B) FT-IR analysis of MSNs@SF-HA-FA. (C) TEM images of the nanoparticles. Scale bars, 100 nm. (D) Particle size measurement by DLS. (E) DLS analysis of particle size stability over 7 consecutive days. Data are represented as mean ± SD. The optimal size range for drug delivery carriers is generally considered to be 100–200 nm, as nanoparticles within this range are more favorable for efficient accumulation at tumor sites.44 To determine the particle size of MSNs@SF-HA-FA, dynamic light scattering (DLS) analysis was performed (Figure 5D). The results showed that the average diameter of bare MSNs was approximately 90 nm. After SF loading and HA-FA surface modification, the particle size increased to approximately 120 nm, remaining within the optimal 100–200 nm range, indicating suitability for effective tumor-targeted drug delivery. In addition, DLS measurements demonstrated that the particle sizes of both MSNs and MSNs@SF-HA-FA remained nearly unchanged over one week (Figure 5E), suggesting good colloidal stability of MSNs@SF-HA-FA. The crystalline structures of MSNs, MSNs@SF-HA, and MSNs@SF-HA-FA were further characterized by X-ray diffraction (XRD). As shown in Figure 6B, calcined MSNs exhibited a typical broad diffraction peak at approximately 22°, consistent with the standard pattern of amorphous silica (JCPDS 29–0085), indicating that the synthesized MSNs possessed a typical amorphous structure. After SF loading and HA/FA modification, the overall XRD pattern of MSNs@SF-HA-FA remained similar to that of bare MSNs, with no additional crystalline diffraction peaks or significant peak shifts observed. These results suggest that SF was dispersed or encapsulated in an amorphous state within the nanoparticles without forming an independent crystalline phase. Moreover, the drug loading and surface functionalization processes did not disrupt the structural framework of the MSNs, indicating that this construction strategy enables drug loading and functional modification while preserving the structural integrity of the mesoporous silica matrix. In vitro drug release studies (Figure 6A) demonstrated that, compared with free SF, MSNs@SF-HA exhibited a sustained and gradual release profile, which helps reduce burst release and improves the controlled release performance of the drug. Characterization, cytotoxicity, and cellular uptake of MSNs-HA-FA (A) In vitro drug release profile of MSNs-HA-FA. (B) XRD pattern of MSNs-HA-FA. (C) CCK-8 assay assessing the cytotoxicity of MSNs-HA-FA (n = 6, n represents biological replicates). (D) Fluorescence imaging showing the cellular uptake of MSNs-HA-FA (n = 3, n represents biological replicates), scale bars, 50 μm. Data are represented as mean ± SD. An ideal drug delivery system should enhance the targeting of the delivered drug while minimizing its toxicity to normal cells.45 Therefore, to evaluate the cytotoxicity of MSNs@SF-HA-FA, we used the CCK-8 assay to assess the effects of the blank carrier MSNs-HA-FA on the viability of normal human lung epithelial cells (BEAS-2B) and lung cancer cells (95C and 95D) at different concentrations and time points. CCK-8 assay results (Figure 6C) demonstrated that the cell viability of BEAS-2B, 95C, and 95D cells remained above 85% at both 24 and 48 h, even when the concentration of MSNs-HA-FA reached 1000 μg/mL, indicating that MSNs-HA-FA exhibited low cytotoxicity. Efficient intracellular uptake of therapeutic agents by tumor cells is a critical prerequisite for their antitumor efficacy.46 To evaluate the cellular internalization capability of MSNs@SF-HA-FA nanoparticles, the hydrophobic fluorescent probe Nile red was encapsulated into MSNs-HA-FA nanoparticles, and their uptake by 95C cells was observed using confocal laser scanning microscopy (CLSM). As shown in Figure 6D, after 6 h of co-incubation, a distinct red fluorescence signal was detected within cells treated with MSNs@Nile red-HA-FA. When the incubation time was extended to 24 h, the fluorescence intensity further increased, indicating effective cellular internalization and time-dependent intracellular accumulation of the nanoparticles. Notably, compared with MSNs@Nile red-HA-FA, free Nile red exhibited stronger intracellular fluorescence at 6 h. However, at 24 h, its fluorescence intensity was lower than that of the nanoparticle-treated group. This difference may be attributed to distinct internalization mechanisms: free Nile red primarily enters cells via passive diffusion, whereas MSNs@Nile red-HA-FA is internalized through endocytosis. Compared with passive diffusion, receptor-mediated endocytosis not only enhances cellular uptake efficiency but also prolongs intracellular retention, thereby facilitating sustained accumulation at tumor sites. Given that MSNs@SF-HA-FA nanoparticles are mainly internalized via endocytosis, their uptake likely depends on specific interactions between surface-modified ligands and tumor cell receptors. Both HA and FA have been widely reported to possess tumor-targeting properties. FA-modified drug delivery systems can enter tumor cells through folate receptor-mediated endocytosis, thereby enhancing drug accumulation in tumor tissues while reducing nonspecific effects on normal tissues.47 Meanwhile, HA, a natural polysaccharide, binds to CD44 receptors, which are highly expressed in various tumor cells. Thus, HA is regarded as a biocompatible tumor-targeting ligand.48 To further verify the independent contributions of HA and FA to cellular uptake, MSNs@Nile red-HA and MSNs@Nile red-FA nanoparticles were constructed and co-incubated with 95C cells for 24 h. As shown in Figure S4, compared with free Nile red, both MSNs@Nile red-HA and MSNs@Nile red-FA exhibited significantly enhanced fluorescence signals, indicating that each ligand independently promoted active nanoparticle internalization. Importantly, the dual-modified MSNs@Nile red-HA-FA group displayed the strongest fluorescence intensity, suggesting a synergistic enhancement effect between HA and FA, resulting in significantly superior cellular uptake efficiency compared with either single-targeting system. In vivo targeting and anti-NSCLC efficacy of MSNs@SF-HA-FA We successfully synthesized MSNs@SF-HA-FA nanoparticles and confirmed their good stability and biocompatibility. Next, we investigated their in vivo biodistribution. MSNs@DiR-HA-FA nanoparticles were administered to tumor-bearing mice via tail vein injection, followed by in vivo imaging analysis. The results (Figure 7A) showed that MSNs@DiR-HA-FA gradually accumulated in the lungs over time. Further ex vivo imaging of major organs revealed the strongest fluorescence signal in lung tumor tissues (Figure 7B). These findings indicate that MSNs@SF-HA-FA nanoparticles exhibit excellent tumor-targeting capability. In vivo targeting and anti-NSCLC efficacy of MSNs@SF-HA-FA (A) In vivo fluorescence imaging analysis (n = 5, n represents the number of mice). (B) Ex vivo fluorescence imaging of major organs (n = 5, n represents the number of mice). (C) Images of lung tumor tissues from mice (n = 5, n represents the number of mice). (D) H&E-stained images and immunohistochemical analysis of SPI1 expression in xenograft tumors (n = 5, n represents the number of mice), scale bars, 100 μm. To further investigate the in vivo anti-NSCLC activity of MSNs@SF-HA-FA, a tumor-bearing mouse model was established and subjected to different treatments. The results (Figures 7C and S5) showed that, compared with the PBS group, both the SF group and the MSNs@SF-HA-FA group exhibited a significant reduction in the number of pulmonary tumor nodules (p < 0.01). Moreover, the therapeutic effect of the MSNs@SF-HA-FA group was superior to that of the SF group, indicating that MSNs@SF-HA-FA possesses enhanced anti-NSCLC activity. H&E staining results corroborated this observation (Figure 7D). Moreover, IHC analysis (Figure 7D) revealed that both the SF and MSNs@SF-HA-FA treatments significantly decreased SPI1 expression compared with the PBS group, with the MSNs@SF-HA-FA group showing the most pronounced reduction. Taken together with previous experimental results, these findings demonstrate that MSNs@SF-HA-FA can effectively inhibit SPI1 expression, thereby exerting potent anti-NSCLC effects. Biosafety of MSNs@SF-HA-FA Good biocompatibility is considered a fundamental requirement for the biomedical application of nanomaterials.49 To evaluate the in vivo safety of the MSNs@SF-HA-FA nanosystem, histological examinations of major organs (heart, liver, spleen, and kidney) were first performed using H&E staining. As shown in Figure 8A, compared with the PBS group, no obvious histopathological abnormalities or inflammatory lesions were observed in the major organs of mice treated with MSNs@SF-HA-FA. Furthermore, liver and renal functions were assessed by analyzing serum biochemical parameters. The results (Figure 8B) demonstrated that ALT and AST, indicators of hepatocellular integrity, as well as blood urea nitrogen (BUN) and CREA, markers of glomerular filtration function, showed no significant differences between the MSNs@SF-HA-FA group and the PBS group (p > 0.05). All measured parameters remained within normal physiological ranges. Taken together, the histological and serum biochemical findings indicate that, at the administered dosage and treatment duration used in this study, MSNs@SF-HA-FA did not induce evident organ toxicity and exhibited favorable in vivo biosafety. In vivo biosafety of MSNs@SF-HA-FA (A) Representative H&E staining of major organs (heart, liver, spleen, and kidney) from mice in each group (n = 3, n represents the number of mice), scale bars, 200 μm. (B) Serum levels of AST, ALT, BUN, and CREA measured using an automated biochemical analyzer (n = 5, n represents the number of mice). Data are represented as mean ± SD. Discussion SPI1 has been confirmed to be aberrantly overexpressed in NSCLC and to participate in its initiation and progression.20 However, its precise mechanisms remain incompletely understood. Our previous study demonstrated that SF can inhibit EMT and metastasis in NSCLC by suppressing the miR-616-5p-mediated GSK3β/β-catenin signaling pathway.26 Nevertheless, the interplay among SF, SPI1, and miR-616-5p in NSCLC remains unclear. To elucidate their roles, we first investigated the effects of SPI1 overexpression or knockdown on NSCLC cells in vitro. The results showed that SPI1 promotes NSCLC cell proliferation, migration, and invasion. Further in vitro experiments indicated that SPI1 transcriptionally regulates miR-616-5p expression, while SF exerts its anti-metastatic effects through inhibition of the SPI1/miR-616-5p axis. Additionally, we designed and synthesized a MSNs@SF-HA-FA nanoparticle. In vitro and in vivo studies demonstrated that this nanoparticle possesses excellent morphology, stability, and targeting ability, and can downregulate SPI1 expression to exert anti-NSCLC effects. These findings suggest that SPI1 may serve as a potential therapeutic target for NSCLC, while MSNs@SF-HA-FA represents a promising SF drug delivery system, providing alternative strategies for NSCLC treatment. SPI1, as an oncogenic factor mediating cellular transformation, plays a critical role in tumor initiation and progression.50,51 When the SPI1 proto-oncogene is aberrantly activated in tumors, it leads to the overexpression of the transcription factor SPI1. These SPI1 molecules can upregulate the expression of glycolytic genes and bind to promoters of proliferation-related genes,52 thereby promoting tumor cell glycolysis, malignant proliferation, and invasion.53 Previous studies have shown that SPI1 upregulation enhances proliferation and invasion in gastric cancer cells, whereas SPI1 downregulation produces the opposite effects.52 Similarly, in our study, SPI1 overexpression promoted NSCLC cell proliferation and invasion, while SPI1 silencing inhibited these processes. Furthermore, we observed that SPI1 also enhances NSCLC cell migration, which may be associated with the EMT process. Abnormal activation of EMT is a key driver of cancer metastasis.42 One study reported that SPI1 is positively correlated with EMT-related gene signatures,54 and it has been demonstrated that SPI1 participates in EMT transitions.55 Moreover, SPI1 can activate TGF-β1.55 Tumor-derived TGF-β1 mediates malignant remodeling of the tumor microenvironment56 and serves as a potent inducer of mesenchymal transition in various human cancers.57 These findings suggest that SPI1-induced migration may be mediated through the promotion of EMT. Furthermore, SPI1, as a member of the ETS transcription factor family, possesses a highly conserved DNA-binding domain known as the ETS domain, similar to other family members.58 This domain can regulate transcription of target gene promoters by specifically binding to nearby PU boxes containing purine-rich GGAA sequences.59,60 Studies have shown that in hepatocellular carcinoma, SPI1 can upregulate the expression of miR-616-5p.61 In our study, in vitro experiments demonstrated that SPI1 elevates miR-616-5p expression at the transcriptional level and promotes NSCLC cell metastasis. Our previous research has confirmed that miR-616-5p facilitates NSCLC cell migration and metastasis. These results indicate that SPI1 promotes NSCLC migration and metastasis by upregulating miR-616-5p expression, thereby exacerbating NSCLC progression. Dietary factors play a critical role in both the etiology and clinical management of cancer.62 Studies have shown that cruciferous vegetables can reduce cancer risk due to their abundant phytochemicals and precursor compounds. The anticancer activity of these plants is largely attributed to their glucosinolate content, which is enzymatically converted into isothiocyanates (ITCs) in vivo. Among various ITCs, SF has been the most extensively studied.63 Multiple studies have confirmed that SF can effectively inhibit the initiation and progression of diverse cancers, including lung cancer64 and esophageal squamous cell carcinoma.25 In NSCLC, SF has been found to suppress EMT and metastasis through the miR-616-5p-mediated GSK3β/β-catenin signaling pathway.26 Our study further demonstrated that SPI1 can transcriptionally upregulate miR-616-5p. To investigate the relationship between SF, SPI1, and miR-616-5p, we conducted molecular docking and related cellular experiments. The results showed that SF can directly bind to SPI1 and inhibit its activity, thereby downregulating miR-616-5p and exerting therapeutic effects against NSCLC. The inhibition of SPI1 activity by SF may involve the NF-κB signaling pathway and TGF-β1. In NSCLC, activated NF-κB signaling is closely associated with cell proliferation, apoptosis, angiogenesis, EMT, inflammation, and metastasis.65 Moreover, TGF-β1, the predominant isoform of TGF-β in NSCLC,66 is a major cytokine that induces EMT and regulates tumor migration and invasion through both canonical TGF-β/Smad and non-canonical TGF-β/ERK signaling pathways.67 Studies have shown that SPI1 can activate NF-κB and TGF-β1 signaling,68 whereas SF effectively inhibits NF-κB activation and TGF-β1-induced migration.69 These findings suggest that SF may suppress the SPI1/miR-616-5p axis by inhibiting NF-κB and TGF-β1 activation, thereby mitigating NSCLC metastasis. Although SF can effectively suppress NSCLC metastasis, its instability under various conditions and rapid intracellular accumulation and metabolism limit its clinical application. Therefore, developing an appropriate drug delivery system is of critical importance.30 In this study, we designed and successfully prepared a nanodelivery system, MSNs@SF-HA-FA, in which MSNs serve as the carrier, and surface modification with HA and FA enables efficient SF delivery. Studies have shown that the particle size of nanomaterials significantly affects their biodistribution. Nanoparticles smaller than 10 nm can be rapidly cleared by the kidneys, while those larger than 200 nm activate the complement system and are quickly removed from the bloodstream.70 Conversely, nanoparticles with sizes ranging from 20 to 200 nm can passively accumulate in tumor tissues more effectively than in normal tissues.37 In this study, MSNs@SF-HA-FA exhibited a particle size of 120 nm, within the 20–200 nm range, suggesting its suitability for targeted drug delivery. Further in vitro release experiments demonstrated that MSNs@SF-HA-FA possesses sustained-release properties, likely because SF is encapsulated within the MSN core and its surface is modified with HA and FA, creating a barrier to drug release.71 This sustained-release pattern may delay drug exposure in tumor cells, potentially enhancing therapeutic efficacy. Moreover, in vivo experiments indicated that MSNs@SF-HA-FA exhibits low cytotoxicity, promotes cellular uptake, enhances tumor targeting, and improves the therapeutic effect of SF against NSCLC. This phenomenon is likely associated with the surface modification by HA and FA, as CD44 and FR are the respective receptors for HA and FA, both of which are highly expressed on NSCLC cell surfaces.39,71 Upon conjugation with HA and FA, the drug carrier selectively binds to CD44 and FR overexpressed in NSCLC cells, enters the cells, and releases the drug under enzymatic action, effectively targeting tumor cells while minimizing cytotoxicity to normal cells and reducing adverse effects.72 In summary, these findings indicate that MSNs@SF-HA-FA is a promising SF drug delivery system capable of significantly enhancing the therapeutic efficacy of SF against NSCLC. In summary, this study reveals that SPI1 promotes NSCLC cell proliferation, migration, and invasion, and can transcriptionally upregulate the expression of miR-616-5p. Further investigations demonstrated that SF can inhibit NSCLC metastasis by modulating the SPI1/miR-616-5p axis. Moreover, we successfully developed SF-loaded MSNs@HA-FA nanoparticles (MSNs@SF-HA-FA). Both in vitro and in vivo experiments indicated that MSNs@SF-HA-FA possess favorable morphology and biocompatibility, and can effectively enhance the inhibitory effect of SF on NSCLC metastasis. These findings suggest that the SPI1/miR-616-5p axis may serve as a potential therapeutic target for SF in treating NSCLC metastasis, and MSNs@SF-HA-FA holds promise as a targeted drug delivery system for combating NSCLC metastasis. Limitations of the study Despite systematically elucidating the role of the SPI1/miR-616-5p axis in NSCLC metastasis and demonstrating the therapeutic potential of MSNs@SF-HA-FA, several limitations should be acknowledged. First, the direct interaction between SF and SPI1 is currently supported mainly by molecular docking and SPR analyses, and the precise binding sites and structural basis remain to be further validated. Second, the downstream target genes of miR-616-5p and the key signaling pathways it mediates have not been fully explored and warrant further investigation. In addition, the in vivo experiments in this study were primarily conducted using xenograft models, which may not fully recapitulate the clinical tumor microenvironment, and thus require validation in more clinically relevant models. Finally, the long-term in vivo safety and potential off-target effects of the nanosystem remain to be systematically evaluated. Resource availability Lead contact Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Daxuan Wang (daxanwang@163.com). Materials availability All data associated with this study are available in the article or the online supplemental information. Data and code availability Data requests should be directed to and will be fulfilled by the lead contact. The study in this article does not report original code. Additional information will be made available by the lead contact upon request. Acknowledgments This work was supported by a Fund for the Scientific and Technological Innovation Joint Capital Projects of Fujian Province of China (2021Y9020), a Fund for 2025 Fujian Provincial Natural Science Foundation General Project (2025J01504), and a Fund for Fujian Provincial Health Science and Technology Plan Youth Project Fund (2024QNA008). Author contributions Conceptualization: D.W. and B.X.; methodology: W.L., C.L., H.X., and Y.X.; investigation: W.L., C.L., H.X., and Y.X.; formal analysis: W.L., C.L., H.X., and W.Y.; data curation: W.L., C.L., and W.Y.; validation: H.X.; resources: B.X. and D.W.; funding acquisition: W.L. and D.W.; project administration: B.X. and D.W.; supervision: B.X. and D.W.; writing – original draft: W.L., C.L., B.X., and D.W.; writing: editing and revision: W.L., C.L., B.X., and D.W. Declaration of interests The authors declare no competing interests. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesSPI1AbcamCat#EPR25123-110; RRID: AB_3741646N-cadherinProteintechCat#22018-1-AP; RRID: AB_2813891E-cadherinProteintechCat#20874-1-AP; RRID: AB_10697811VimentinAbcamCat#ab137321; RRID: AB_2921312Bacterial and virus strainsLentiviral SPI1 overexpression virusGeneChemN/ALentiviral negative control virusGeneChemN/ALentiviral shRNA targeting human SPI1GeneChemN/ALentiviral non-targeting control shRNAGeneChemN/AChemicals, peptides, and recombinant proteinsRPMI-1640GibcoCat#11875093MethanolAladdinCat#433275Crystal VioletBeyotimecat#Y268091Fetal Bovine SerumGibcoCat#10091148Penicillin-Streptomycin (Pen/Strep) solutionProcell systemCat#PB180120ParaformaldehydeSolarbioCat#P1110Phosphate buffer solutionSolarbioCat#C1032TRIzol ReagentInvitrogenTMCat#15596018CNDiaminodiamideBeyotimeCat#P0203SulforaphaneAladdinCat#S111997Glycine hydrochloride bufferSigmaCat#G2879Hexadecyltrimethylammonium bromide (CTAB)AladdinCat#H432954NaOHAladdinCat#S774711tetraethyl orthosilicate (TEOS)AladdinCat#T110595ethanolAladdinCat#E1521120DichloromethaneAladdinCat#D1522471branched polyethyleneimineAladdinCat#E107078Hyaluronic acid (HA)AladdinCat#H758878N-hydroxysuccinimide (NHS)AladdinCat#H1093301-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)AladdinCat#E106172(3-aminopropyl) trimethoxysilane (APTES)AladdinCat#A107148Folic acid (FA)AladdinCat#F103635N,N-dimethylformamide (DMF)AladdinCat#D742341Nile redAladdinCat#N121291DAPIBeyotimeCat# C1002DiRAladdinCat#D1310312% IsofluraneRWDCat#R510-22-10Hematoxylin and eosinBeyotimeCat#C0105MCritical commercial assaysBCA Protein Assay KitBeyotimeCat#P0011Cell Counting Kit-8 (CCK-8) assay kitBeyotimeCat#C0037Reverse transcription kitAPExBIOCat#K1074HotStartTM Universal 2X Green qPCR Master MixAPExBIOCat#K1170Experimental models: Cell linesBEAS-2Bthe Shanghai Cell Bank of Chinese Academy of SciencesCat#GNHu27; RRID: CVCL_016895CstemrecellCat#STM-CL-5379; RRID: CVCL_710995Dthe Shanghai Cell Bank of Chinese Academy of SciencesCat#TCHu 61; RRID: CVCL_7110Experimental models: Organisms/strainsBALB/c nude miceSiPeiFuRRID: IMSR_CRL:194OligonucleotidesshSPI1:5′-AGCAGATGACGTCCTCGATA-3′This paperN/APrimer: miR-616-5p-F: GCCGAGACTCAAAACCCTTCAGThis paperN/APrimer: miR-616-5p-R: TGGTGTCGTGGAGTCGThis paperN/APrimer: U6-F: CTCGCTTCGGCAGCACAThis paperN/APrimer: U6-R: AACGCTTCACGAATTTGCGTThis paperN/ASoftware and algorithmsTransmiR v3.0N/Ahttp://www.cuilab.cn/transmihTFtargetN/Ahttps://guolab.wchscu.cn/hTFtarget/#!/targets/gene?gene=ENSG00000208028ImageJNIHRRID: SCR_003070PubChemN/Ahttps://pubchem.ncbi.nlm.nih.gov/Protein Sequence DatabaseN/Ahttps://www.rcsb.orgPyMOLSchrödingerhttps://pymol.org/OpenBabeN/Ahttps://openbabel.org/index.htmlAutoDockToolsScripps Researchhttps://autodock.scripps.edu/Bia EvaluationGE HealthcareN/AChem3DChemistry Softwarehttps://library.bath.ac.uk/chemistry-software/chem3dGraphPad Prism 9GraphPad Softwarehttps://www.graphpad.com/features Experimental model and study participant details Cell culture The immortalized human bronchial epithelial cell line BEAS-2B and the human lung cancer cell lines 95D were obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences, while the human lung cancer cell line 95C was purchased from Stem Recell (Shanghai, China). All cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin. Cells were maintained at 37°C in a humidified incubator with 5% CO2. All cell lines were STR validated and were verified as mycoplasma negative. Animal Twenty-five 6-week-old male BALB/c nude mice were purchased from SiPeiFu (Beijing, China). All animal experiments were conducted in accordance with the ARRIVE guidelines. The study protocol was approved by the Laboratory Animal Ethics Committee of Wenzhou Medical University (Approval No. wydw2025-0526). As only male mice were used in this study, the direct influence of sex on the in vivo experimental results cannot be determined, and this represents a limitation of the study in assessing sex-specific responses. Method details Cell transfection Specific short hairpin RNA targeting SPI1 (sh-SPI1) and the SPI1 overexpression construct (OE-SPI1) were purchased from GeneChem (Shanghai, China). A lentiviral vector carrying OE-SPI1 (GeneChem, Shanghai, China) was transduced into 95C cells. Briefly, 95C cells were prepared as a single-cell suspension using infection medium and seeded into 12-well plates at a density of 5 × 105 cells per well, followed by infection with the lentivirus. The culture medium was replaced 12 h post-transduction. When the infection efficiency exceeded 70%, cells were harvested for subsequent experiments. In addition, SPI1 knockdown experiments in 95D cells were performed using the same procedure. Western blot assay After protein extraction from cells or tissues, protein concentrations were determined using a Micro BCA Protein Assay Kit (Beyotime, Shanghai, China). Equal amounts of protein samples were separated on 10% SDS–polyacrylamide gels and transferred onto polyvinylidene fluoride (PVDF) membranes, which were then blocked with 5% non-fat milk. The membranes were incubated overnight at 4°C with primary antibodies against SPI1 (1:1000, Abcam, Cambridge, UK), N-cadherin (1:2000, Proteintech, Wuhan, China), E-cadherin (1:20000, Proteintech, Wuhan, China), Vimentin (1:2000, Abcam, Cambridge, UK), and GAPDH (1:50000, Proteintech, Wuhan, China). After incubation with the corresponding secondary antibodies at room temperature for 30 min, protein bands were visualized using a chemiluminescence imaging system. Band intensities were quantified with Image J software. CCK-8 assay Cell viability was assessed using a CCK-8 assay kit (Beyotime, Shanghai, China). Briefly, treated 95C and 95D cells were seeded into 96-well plates at a density of 2000 cells per well. After incubation, 10 μL of CCK-8 solution was added to each well, followed by incubation at 37°C for 1 h in the dark. Absorbance was then measured at 450 nm using a microplate reader. Cell colony formation assay Treated cells from each group were seeded into 6-well plates at a density of 1000 cells per well and cultured for 1–2 weeks to allow colony formation. The culture medium was replaced every 3 days. Colonies were then fixed with methanol and stained with 0.1% crystal violet. Finally, colony images were captured, and the number of colonies was quantified. Transwell assay Transwell assays were performed to evaluate the effect of SPI1 expression on cell migration and invasion. Briefly, 0.3 mL of treated cell suspension (3 × 105 cells/mL) was seeded into the upper chamber of a Transwell insert. For invasion assays, the upper chamber was precoated with 80 μL of Matrigel. The lower chamber was filled with 0.7 mL of complete medium containing 10% FBS. After incubation at 37°C with 5% CO2 for 24 h, non-migrated or non-invaded cells were removed, and cells that had traversed the membrane were fixed and stained with 0.5% crystal violet. The stained cells were then imaged and quantified under a microscope. Immunohistochemical staining NSCLC tissues and adjacent normal tissues were fixed in 4% paraformaldehyde for 24 h, embedded in paraffin, and sectioned into 4 μm slices. Following drying, deparaffinization, and rehydration, sections were subjected to antigen retrieval in citrate buffer under 121°C autoclaving for 90 s. After washing with PBS, sections were blocked with goat serum (Gibco) and incubated with anti-SPI1 antibody (Abcam). Following PBS washes, the sections were incubated with a detection system (OriGene Technologies). Sections were then counterstained with hematoxylin for 50 s at room temperature and observed under a light microscope. The clinical study protocol of this research was approved by the Ethics Committee of Fuzhou University Affiliated Provincial Hospital (Approval No. K2022-05-005), and written informed consent was obtained from all participants. RT-PCR Total RNA was extracted using TRIzol reagent according to the manufacturer’s instructions. RT-PCR were performed following the protocols of the respective kits, with U6 serving as the internal control. The relative expression of miR-616-5p was calculated using the 2-ΔΔCT method, and all experiments were performed in triplicate. The primer sequences were as follows: miR-616-5p-F, 5′-GCCGAGACTCAAAACCCTTCAG-3′; miR-616-5p-R, 5′-TGGTGTCGTGGAGTCG-3′; U6-F, 5′-CTCGCTTCGGCAGCACA-3′; U6-R, 5′-AACGCTTCACGAATTTGCGT-3′. Transcription factor prediction To identify the potential upstream transcription factors of miR-616-5p, we performed bioinformatic predictions using the TransmiR v3.0 database (http://www.cuilab.cn/transmir) and the hTFtarget platform (https://guolab.wchscu.cn/hTFtarget/#!/targets/gene?gene=ENSG00000208028). Transcription factors overlapping between the two prediction results were selected for further analysis. Luciferase activity assay As previously described,55,73 the miR-616-5p promoter region containing the predicted SPI1 binding sites was cloned and transfected into 95D cells. Luciferase activity was measured using the Dual-Luciferase® Reporter Assay System (Promega Corporation, Madison, WI, USA) according to the manufacturer’s instructions. IHC Immunohistochemical staining for SPI1 was performed on paraffin-embedded tumor tissues. The sections were incubated with a primary anti-SPI1 antibody (Abcam) overnight at 4°C. After washing, the slides were incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h, followed by visualization using 3,3′-diaminobenzidine (DAB). The staining intensity was analyzed using NIH ImageJ software. Molecular docking The 2D structure of sulforaphane was obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) in .sdf format and converted to a 3D structure using Chem3D software. The structure was energy-minimized to obtain the most stable conformation. The 3D structure of SPI1 was retrieved from the Protein Data Bank (https://www.rcsb.org/) in .PDB format. Water molecules and ligands were removed from the protein structure using PyMOL. The pdb file was then converted to pdbqt format using OpenBabel, and molecular docking between the macromolecular receptor (SPI1) and the small-molecule ligand (sulforaphane) was performed using AutoDockTools. Finally, the docking results were visualized using PyMOL.74 SPRi The PlexArray® HT system (Plexera, Woodinville, WA, USA), based on the principle of SPRi, was used to monitor receptor–ligand binding and dissociation in real time to evaluate the interaction between SPI1 and sulforaphane. Briefly, a three-dimensional dextran chip immobilized with 0.15 mg/mL SPI1 protein was fixed on the sensor surface, and sulforaphane at different concentrations (2.5, 5.0, 10, 20, and 40 μM) was injected through the flow cell in aqueous solution. A 10 mM glycine–HCl buffer (pH 2.0) was used for regeneration. All measurements were performed at 22°C with a flow rate of 120 μL/min. Kinetic curves were obtained using BIA evaluation software, and the equilibrium dissociation constant (KD) was calculated.75 Preparation of MSNs 1 g of cetyltrimethylammonium bromide (CTAB) as a surfactant and 1.4 mL of 1 M NaOH were added to 97 mL of deionized water, stirred, and maintained at 80°C until the solution became clear. Subsequently, 1 mL of 98% tetraethyl orthosilicate (TEOS) was added dropwise, followed by stirring for 2 h. The product was washed three times with water and ethanol, and then calcined to obtain MSNs. Preparation of MSNs@SF-HA Thirty milligrams of MSNs were mixed with 15 mg of sulforaphane (SF) in 2 mL of dichloromethane and stirred for 24 h. The nanoparticles were then collected by centrifugation and vacuum-dried at room temperature for 12 h to obtain MSNs@SF. Next, 30 mg of MSNs@SF was dispersed in 4 mL of phosphate-buffered saline (PBS, 10 mM, pH 7.4), and 100 μL of branched polyethyleneimine (PEI, 75 mg/mL) was added, followed by stirring at room temperature for 30 min. The product was centrifuged (10200 rpm, 15 min) and washed three times with ultrapure water to yield MSNs@SF-PEI. Subsequently, 15 mg of HA, 40 mg of N-hydroxysuccinimide (NHS), and 30 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) were dissolved in 10 mL of distilled water and stirred for 1 h to activate the carboxyl groups of HA. MSNs@SF-PEI were then added to the mixture and stirred at room temperature for 24 h. Finally, the nanoparticles were collected by centrifugation, washed, and lyophilized overnight to obtain MSNs@SF-HA.76 Preparation of MSNs@SF-HA-FA One hundred microliters of (3-aminopropyl) trimethoxysilane (APTES) was rapidly added to 40 mL of an MSNs@SF-HA ethanol suspension and gently stirred at room temperature for 24 h. The resulting MSNs@SF-HA-NH2 were collected by centrifugation and washed three times with ethanol. Subsequently, 20 mg of folic acid (FA), 10 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), and 8 mg of NHS were dissolved in 20 mL of anhydrous dimethylformamide (DMF) and incubated overnight at room temperature to activate the carboxyl groups of FA. MSNs@SF-HA-NH2 (20 mg) were then added to the activated FA solution and reacted for 12 h. After the reaction, the product was collected by centrifugation (12000 rpm, 20 min) to obtain MSNs@SF-HA-FA, which was subsequently washed three times with methanol.77 Characterization of MSNs@SF-HA-FA The chemical modification of MSNs was confirmed by Fourier-transform infrared spectroscopy (FTIR), and the morphology of the synthesized nanoparticles was observed using transmission electron microscopy (TEM). Dynamic light scattering (DLS) was employed to determine the particle size and hydrodynamic diameter of the nanoparticles. The zeta potentials of MSNs, MSNs@SF, MSNs@SF-PEI, MSNs@SF-HA, and MSNs@SF-HA-FA nanoparticles were measured using a Zetasizer Nano ZS instrument (Malvern Instruments, UK). Finally, X-ray diffraction (XRD) patterns of MSNs, MSNs@SF-HA, and MSNs@SF-HA-FA were analyzed using an X’Pert PRO MPD diffractometer (Panalytical, Amsterdam, The Netherlands). In vitro drug release In vitro drug release of MSNs@SF-HA-FA was evaluated using a dialysis method. Free SF (1 mg) and MSNs@SF-HA-FA (equivalent to 1 mg of SF) were each dispersed in 1 mL of water and placed into dialysis membranes, which were then immersed in 50 mL beakers containing 40 mL of PBS. During the experiment, the external solution was continuously stirred at 100 rpm and maintained at 37 °C. Samples were collected at predetermined time intervals and replaced with an equal volume of fresh release medium. The cumulative release of SF was determined by high-performance liquid chromatography (HPLC).78 In vitro cytotoxicity BEAS-2B, 95C, and 95D cells were seeded into 96-well plates at a density of 5000 cells per well and treated with culture medium containing different concentrations of MSNs-HA-FA (0, 100, 200, 400, 600, 800, and 1000 μg/mL) for 24 h and 48 h. Cell viability was then assessed using a CCK-8 assay kit, following the manufacturer’s instructions. In vitro cellular uptake Cellular uptake of MSNs@SF-HA-FA by 95C cells was investigated using confocal laser scanning microscopy (CLSM). Nile red was encapsulated into MSNs-HA-FA following the same preparation method as MSNs@SF-HA-FA. After encapsulation, Free Nile red and MSNs@Nile red-HA-FA were incubated with 95C cells for 6 h or 24 h. Cells were then washed with PBS, fixed with 4% paraformaldehyde (PFA), washed again with PBS, and counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Cellular uptake was finally observed under CLSM.79 To further investigate the independent contributions of HA and FA to cellular uptake, MSNs@Nile red-HA and MSNs@Nile red-FA nanoparticles were prepared and incubated with 95C cells for 24 h. Subsequently, cells were washed with PBS, fixed with 4% paraformaldehyde (PFA), counterstained with DAPI, and observed under a confocal laser scanning microscope (CLSM) to evaluate the uptake of the respective nanoparticles. In vivo imaging of MSNs@SF-HA-FA using the IVIS system Overexpressing SPI1 95C cells (5 × 106 cells per mouse) were injected into BALB/c nude mice (n = 5) via the tail vein to establish a tumor-bearing mouse model. When the tumor volume reached 80 mm3, mice were intravenously injected with MSNs@DiR-HA-FA (1 mg/mL, 20 μL), in which the fluorescent dye DiR was used as a substitute for SF to prepare MSNs@DiR -HA-FA. Prior to imaging, mice were anesthetized with 2% isoflurane. Fluorescence images were acquired at 3, 6, 12, 24, and 48 h post-injection using a PerkinElmer IVIS Spectrum system. After euthanasia, the heart, liver, spleen, lungs, and kidneys were collected under the same conditions for observation, and the fluorescence intensity within selected ROIs was quantified using imaging software. In vivo anti-NSCLC activity of MSNs@SF-HA-FA The tumor-bearing mouse model was established using the same method as described for the imaging experiment. When tumor volumes reached approximately 80 mm3, 20 BALB/c nude mice were randomly divided into four groups (n = 5 per group): PBS, SF, MSNs, and MSNs@SF-HA-FA. Each group received treatment via tail vein injection with PBS, SF, MSNs, or MSNs@SF-HA-FA (equivalent to 5 mg/kg SF) every 2 days. After 4 weeks of treatment, all mice were euthanized, and tumor tissues were collected for subsequent analyses. Pathological examination Histopathological changes in mouse tumor tissues were assessed using hematoxylin and eosin (H&E) staining. Tumor tissues were fixed in 4% paraformaldehyde, dehydrated, embedded in paraffin, and sectioned at 5 μm thickness. Sections were then stained with H&E, followed by washing, mounting, and drying, and histopathological changes were observed under a light microscope. In vivo safety of MSNs@SF-HA-FA After euthanasia, blood samples were collected from mice in the PBS and MSNs@SF-HA-FA groups. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (CREA) were measured using an automated biochemical analyzer (CL6000i, Mindray). Meanwhile, the heart, liver, spleen, and kidney tissues were harvested, sectioned, and subjected to hematoxylin and eosin (H&E) staining to evaluate histopathological changes in the major organs. Quantification and statistical analysis All experiments were performed at least three times. Data are presented as mean ± standard deviation (SD). Statistical analyses were conducted using GraphPad Prism 9 (GraphPad Inc., San Diego, CA, USA). Comparisons between two groups were performed using Student's t-test, while multiple-group comparisons were analyzed by one-way analysis of variance (ANOVA). A p-value of <0.05 was considered statistically significant. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.isci.2026.116293. Contributor Information Baosong Xie, Email: xbasong@126.com. Daxuan Wang, Email: daxanwang@163.com. Supplemental information Document S1. Figures S1–S5 References Associated Data Supplementary Materials Document S1. Figures S1–S5 Data Availability Statement Data requests should be directed to and will be fulfilled by the lead contact. The study in this article does not report original code. Additional information will be made available by the lead contact upon request.